SCHEMBL14975476

SCHEMBL14975476

CSc1ncc(C(N)=O)c(Nc2cccc(Cl)c2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ SYK P43405 11/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ PIM1 P11309 2/20 0.50
▸ PIM2 Q9P1W9 1/20 0.50
▸ CSF1R P07333 1/20 0.50
▸ MAPK8 P45983 1/20 0.49
▸ MAPK9 P45984 1/20 0.49
▸ PDE4B Q07343 1/20 0.48
▸ AURKB Q96GD4 2/20 0.48
▸ ZAP70 P43403 1/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ EGFR P00533 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ ROCK2 O75116 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ HCK P08631 1/20 0.48
▸ ROS1 P08922 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17340292 0.87 SYK (0.55) SYKMAPK1HTTMAPK8MAPK9
SCHEMBL15631821 0.86 SYK (0.72) SYKMAPK1HTTMAPK8MAPK9
SCHEMBL1313173 0.85 MAPK8 (0.58) SYKMAPK1HTTMAPK8MAPK9
SCHEMBL14981500 0.84 SYK (0.78) MEN1KMT2ASYKMAPK1HTT
SCHEMBL2627254 0.83 SYK (0.63) SYKMAPK1HTTMAPK8MAPK9
SCHEMBL17191599 0.82 MAPK8 (0.53) SYKMAPK1HTTMAPK8MAPK9
SCHEMBL2627323 0.81 SYK (0.67) SYKZAP70KCNH2JAK2FLT3
SCHEMBL2627294 0.80 SYK (0.62) SYKMAPK1HTTMAPK8MAPK9
SCHEMBL31357045 0.80 MEN1 (0.53) MEN1KMT2ASYKMAPK1HTT
SCHEMBL26109543 0.80 MEN1 (0.53) MEN1KMT2ASYKMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323418-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-30 — — US disclosed
US-20140323418-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-30 — — US disclosed
US-20140323418-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-30 — — US disclosed
EP-2782580-A1 SELECTIVE KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2014-10-01 — — EP disclosed
WO-2013078468-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed
WO-2013078468-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323418-A1 SELECTIVE KINASE INHIBITORS SYK, BTK, LCK MEN1 4436/4885KMT2A 1542/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback